Hasan Turan1, Salvatore Giovanni Vitale2, Ilker Kahramanoglu3, Luigi Della Corte4, Pierluigi Giampaolino5, Asli Azemi6, Sinem Durmus6, Veysel Sal7, Nedim Tokgozoglu8, Tugan Bese9, Macit Arvas10, Fuat Demirkiran9, Remise Gelisgen6, Sennur Ilvan11, Hafize Uzun6. 1. Department of Gynecologic Oncology, Health Science University, Cam Sakura Training and Research Hospital, Istanbul, Turkey. 2. Obstetrics and Gynecology Unit, Department of General Surgery and Medical Surgical Specialties, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy. sgvitale@unict.it. 3. Department of Gynecologic Oncology, Emsey Hospital, Istanbul, Turkey. 4. Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples, Naples, Italy. 5. Department of Public Health, University of Naples Federico II, Via Sergio Pansini, Naples, Italy. 6. Department of Biochemistry, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. 7. Department of Obstetrics and Gynecology, Memorial Bahcelievler Hospital, Istanbul, Turkey. 8. Department of Gynecologic Oncology, Okmeydanı Training and Research Hospital, Istanbul, Turkey. 9. Department of Gynecologic Oncology, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. 10. Department of Gynecologic Oncology, American Hospital, Istanbul, Turkey. 11. Department of Pathology, School of Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Abstract
PURPOSE: This study aimed to evaluate trefoil factor 3 (TFF3), secreted frizzled-related protein 4 (sFRP4), reactive oxygen species modulator 1 (Romo1) and nuclear factor kappa B (NF-κB) as diagnostic and prognostic markers of endometrial cancer (EC) and ovarian cancer (OC). METHODS: Thirty-one patients with EC and 30 patients with OC undergone surgical treatment were enrolled together with 30 healthy controls in a prospective study. Commercial ELISA kits determined serum TFF-3, Romo-1, NF-кB and sFRP-4 concentrations. RESULTS: Serum TFF-3, Romo-1 and NF-кB levels were significantly higher in patients with EC and OC than those without cancer. Regarding EC, none of the serum biomarkers differs significantly between endometrial and non-endometrioid endometrial carcinomas. Mean serum TFF-3 and NF-кB levels were significantly higher in advanced stages. Increased serum levels of TFF-3 and NF-кB were found in those with a higher grade of the disease. Regarding OC, none of the serum biomarkers differed significantly among histological subtypes. Significantly increased serum levels of NF-кB were observed in patients with advanced-stage OC than those with stage I and II diseases. No difference in serum biomarker levels was found between those who had a recurrence and those who had not. The sensibility and specificity of these four biomarkers in discriminating EC and OC from the control group showed encouraging values, although no one reached 70%. CONCLUSIONS: TFF-3, Romo-1, NF-кB and SFRP4 could represent new diagnostic and prognostic markers for OC and EC. Further studies are needed to validate our results.
PURPOSE: This study aimed to evaluate trefoil factor 3 (TFF3), secreted frizzled-related protein 4 (sFRP4), reactive oxygen species modulator 1 (Romo1) and nuclear factor kappa B (NF-κB) as diagnostic and prognostic markers of endometrial cancer (EC) and ovarian cancer (OC). METHODS: Thirty-one patients with EC and 30 patients with OC undergone surgical treatment were enrolled together with 30 healthy controls in a prospective study. Commercial ELISA kits determined serum TFF-3, Romo-1, NF-кB and sFRP-4 concentrations. RESULTS: Serum TFF-3, Romo-1 and NF-кB levels were significantly higher in patients with EC and OC than those without cancer. Regarding EC, none of the serum biomarkers differs significantly between endometrial and non-endometrioid endometrial carcinomas. Mean serum TFF-3 and NF-кB levels were significantly higher in advanced stages. Increased serum levels of TFF-3 and NF-кB were found in those with a higher grade of the disease. Regarding OC, none of the serum biomarkers differed significantly among histological subtypes. Significantly increased serum levels of NF-кB were observed in patients with advanced-stage OC than those with stage I and II diseases. No difference in serum biomarker levels was found between those who had a recurrence and those who had not. The sensibility and specificity of these four biomarkers in discriminating EC and OC from the control group showed encouraging values, although no one reached 70%. CONCLUSIONS: TFF-3, Romo-1, NF-кB and SFRP4 could represent new diagnostic and prognostic markers for OC and EC. Further studies are needed to validate our results.
Authors: Lindsey A Torre; Britton Trabert; Carol E DeSantis; Kimberly D Miller; Goli Samimi; Carolyn D Runowicz; Mia M Gaudet; Ahmedin Jemal; Rebecca L Siegel Journal: CA Cancer J Clin Date: 2018-05-29 Impact factor: 508.702
Authors: Pierluigi Giampaolino; Virginia Foreste; Luigi Della Corte; Claudia Di Filippo; Giuseppe Iorio; Giuseppe Bifulco Journal: Gland Surg Date: 2020-08
Authors: Giovanni Grandi; Maria Chiara Del Savio; Margaret Sammarini; Laura Cortesi; Angela Toss; Claudia Piombino; Fabio Facchinetti Journal: Eur J Cancer Prev Date: 2020-07 Impact factor: 2.497
Authors: Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2018-09-12 Impact factor: 508.702
Authors: Luigi Della Corte; Pierluigi Giampaolino; Antonio Mercorio; Gaetano Riemma; Antonio Schiattarella; Pasquale De Franciscis; Giuseppe Bifulco Journal: Transl Cancer Res Date: 2020-12 Impact factor: 1.241
Authors: Pierluigi Giampaolino; Valeria Cafasso; Dominga Boccia; Mario Ascione; Antonio Mercorio; Francesco Viciglione; Mario Palumbo; Paolo Serafino; Cira Buonfantino; Maria Chiara De Angelis; Paolo Verrazzo; Giovanna Grasso; Giuseppe Gullo; Giuseppe Bifulco; Luigi Della Corte Journal: Biomed Res Int Date: 2022-09-27 Impact factor: 3.246